{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:53:35Z","timestamp":1790553215212,"version":"4.1.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40257-016-0245-x","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T14:41:00Z","timestamp":1486046460000},"page":"169-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review"],"prefix":"10.1007","volume":"18","author":[{"given":"Alison M.","family":"Layton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anne","family":"Eady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Whitehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbys","family":"Fedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther J.","family":"van Zuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"key":"245_CR1","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134:1527\u201334.","journal-title":"J Invest Dermatol."},{"issue":"Suppl 1","key":"245_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000354887","volume":"27","author":"R Holzmann","year":"2014","unstructured":"Holzmann R, Shakery K. Postadolescent acne in females. Skin Pharmacol Physiol. 2014;27(Suppl 1):3\u20138.","journal-title":"Skin Pharmacol Physiol."},{"key":"245_CR3","first-page":"708","volume":"11","author":"GK Kim","year":"2012","unstructured":"Kim GK, Michaels BD. Post-adolescent acne in women: more common and more clinical considerations. Drugs Dermatol. 2012;11:708\u201313.","journal-title":"Drugs Dermatol."},{"key":"245_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/jwh.2010.2722","volume":"21","author":"AC Perkins","year":"2012","unstructured":"Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB. Acne vulgaris in women: prevalence across the life span. J Women\u2019s Health (Larchmt). 2012;21:223\u201330.","journal-title":"J Women\u2019s Health (Larchmt)."},{"key":"245_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2310\/7750.2008.07053","volume":"12","author":"JK Tan","year":"2008","unstructured":"Tan JK, Li Y, Fung K, Gupta AK, Thomas DR, Sapra S, et al. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. J Cutan Med Surg. 2008;12:235\u201342.","journal-title":"J Cutan Med Surg."},{"key":"245_CR6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/jdv.12061","volume":"27","author":"B Dr\u00e9no","year":"2013","unstructured":"Dr\u00e9no B, Layton A, Zouboulis CC, Lopez-Estebaranz JL, Zalewska-Janowska A, Bagatin E. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27:1063\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"245_CR7","doi-asserted-by":"crossref","unstructured":"Di Landro A, Cazzaniga S, Cusano F, Bonci A, Carla C, Musumeci ML, et al. Adult female acne and associated risk factors: results of a multicenter case-control study in Italy. J Am Acad Dermatol. 2016;75(6):1134\u20131141.e1.","DOI":"10.1016\/j.jaad.2016.06.060"},{"issue":"7","key":"245_CR8","first-page":"19","volume":"7","author":"VD Callender","year":"2014","unstructured":"Callender VD, Alexis AF, Daniels SR, Kawata AK, Burk CT, Wilcox TK, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19\u201331.","journal-title":"J Clin Aesthet Dermatol."},{"key":"245_CR9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaad.2015.05.026","volume":"73","author":"TH Schmidt","year":"2015","unstructured":"Schmidt TH, Shinkai K. Evidence-based approach to cutaneous hyperandrogenism in women. J Am Acad Dermatol. 2015;73:672\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"245_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000347196","volume":"226","author":"MG Cunha da","year":"2013","unstructured":"da Cunha MG, Fonseca FL, Machado CD. Androgenic hormone profile of adult women with acne. Dermatology. 2013;226:167\u201371.","journal-title":"Dermatology"},{"key":"245_CR11","first-page":"275","volume":"16","author":"L Falsetti","year":"2002","unstructured":"Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovarian syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275\u201384.","journal-title":"Gynecol Endocrinol"},{"key":"245_CR12","first-page":"181","volume":"23","author":"L Khondker","year":"2014","unstructured":"Khondker L, Khan SI. Acne vulgaris related to androgens: a review. Mymensingh Med J. 2014;23:181\u20135.","journal-title":"Mymensingh Med J."},{"key":"245_CR13","first-page":"92","volume":"74","author":"WF Bergfeld","year":"2004","unstructured":"Bergfeld WF. The pathophysiology of acne vulgaris in children and adolescents. Part 1. Cutis. 2004;74:92\u20137.","journal-title":"Cutis"},{"key":"245_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/jid.2014.290","volume":"135","author":"M Kistowska","year":"2015","unstructured":"Kistowska M, Meier B, Proust T, Feldmeyer L, Cozzio A, Kuendig T, et al. Propionibacterium acnes promotes Th17 and Th17\/Th1 responses in acne patients. J Invest Dermatol. 2015;135:110\u20138.","journal-title":"J Invest Dermatol."},{"key":"245_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217:27\u201331.","journal-title":"Mol Cell Endocrinol"},{"key":"245_CR16","first-page":"115","volume":"10","author":"E Berardesca","year":"1988","unstructured":"Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G. Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React. 1988;10:115\u20139.","journal-title":"Int J Tissue React."},{"key":"245_CR17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/1523-1747.ep12472325","volume":"100","author":"H Akamatsu","year":"1993","unstructured":"Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5-alpha dihydrotestosterone in vitro. J Invest Dermatol. 1993;100:660\u20132.","journal-title":"J Invest Dermatol."},{"key":"245_CR18","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/S0021-9258(17)37833-X","volume":"254","author":"RH Menard","year":"1979","unstructured":"Menard RH, Guenthner TM, Kon H, Gillette JR. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7\u03b1-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450. J Biol Chem. 1979;254:1726\u201333.","journal-title":"J Biol Chem"},{"key":"245_CR19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(73)92661-5","volume":"2","author":"M Williams","year":"1973","unstructured":"Williams M, Cunliffe WJ. Explanation for premenstrual acne. Lancet. 1973;2:1055\u20137.","journal-title":"Lancet"},{"key":"245_CR20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.clindermatol.2014.05.002","volume":"32","author":"C Lam","year":"2014","unstructured":"Lam C, Zaenglein AL. Contraceptive use in acne. Clin Dermatol. 2014;32:502\u201315.","journal-title":"Clin Dermatol"},{"issue":"Suppl 1","key":"245_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1610-0387.2009.07238.x","volume":"8","author":"R Ganceviciene","year":"2010","unstructured":"Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges. 2010;8(Suppl 1):47\u201359.","journal-title":"J Dtsch Dermatol Ges."},{"key":"245_CR22","unstructured":"Del Rosso JQ, Webster GF, Rosen T, Thiboutot D, Leyden JJ, Gallo R, et al. Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1. Antibiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impact of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use. J Clin Aesthet Dermatol. 2016;9:18\u201324."},{"key":"245_CR23","doi-asserted-by":"crossref","unstructured":"Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne. Cochrane Database Syst Rev. 2009;(2):CD000194.","DOI":"10.1002\/14651858.CD000194.pub2"},{"key":"245_CR24","first-page":"37","volume":"5","author":"GK Kim","year":"2012","unstructured":"Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol. 2012;5:37\u201350.","journal-title":"J Clin Aesthet Dermatol."},{"key":"245_CR25","unstructured":"Rayyan, the systematic reviews web app. https:\/\/rayyan.qcri.org\/ .Accessed 3 Nov 2106."},{"key":"245_CR26","unstructured":"The Cochrane Collaboration\u2019s tool for assessing risk of bias. In: Higgins JPT, Green S (eds). The Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011)]. The Cochrane Collaboration, 2011. www.handbook.cochrane.org . Accessed 3 Nov 2106."},{"key":"245_CR27","unstructured":"Review Manager (RevMan) (computer program). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014."},{"key":"245_CR28","unstructured":"GRADE profiler version 3.6. http:\/\/tech.cochrane.org\/revman\/other-resources\/gradepro\/download . Accessed 3 Nov 2106."},{"key":"245_CR29","unstructured":"Quality of evidence: In: Sch\u00fcnemann H, Bro\u017cek J, Oxman A (eds). GRADE: Handbook for grading quality of evidence and strength of recommendation. Updated October 2013. http:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html . Accessed 3 Nov 2106."},{"key":"245_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0015-0282(16)56518-2","volume":"61","author":"L Cusan","year":"1994","unstructured":"Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994;61:281\u20137.","journal-title":"Fertil Steril"},{"key":"245_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","volume":"111","author":"A Goodfellow","year":"1984","unstructured":"Goodfellow A, Alaghband-Zadeh J, Carter G, Cream JJ, Holland S, Scully J, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209\u201314.","journal-title":"Br J Dermatol"},{"key":"245_CR32","first-page":"455","volume":"59","author":"P Hagag","year":"2014","unstructured":"Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in hirsute women with polycystic ovary syndrome. J Reprod Med. 2014;59:455\u201363.","journal-title":"J Reprod Med"},{"key":"245_CR33","first-page":"84","volume":"68","author":"A Hatwal","year":"1988","unstructured":"Hatwal A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol. 1988;68:84\u20137.","journal-title":"Acta Derm Venereol"},{"key":"245_CR34","first-page":"235","volume":"7","author":"A Kriplani","year":"2009","unstructured":"Kriplani A, Thulkar J, Agrawal N, Kulshrestha V, Ammini AC, Kumar G. A comparative study of Diane-35 plus spironolactone and Diane-35 plus finasteride in cases of hirsutism and acne. Int J Endocrinol Metab. 2009;7:235\u201341.","journal-title":"Int J Endocrinol Metab."},{"key":"245_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/jog.12543","volume":"41","author":"S Leelaphiwat","year":"2015","unstructured":"Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M, Rattanasiri S, et al. Comparison of desogestrel\/ethinylestradiol plus spironolactone versus cyproterone acetate\/ethinylestradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res. 2015;41:401\u201310.","journal-title":"J Obstet Gynaecol Res."},{"key":"245_CR36","first-page":"1","volume":"17","author":"A Mansurul","year":"2000","unstructured":"Mansurul A, Islam AZM. Effect of spironolactone on acne vulgaris: a double blind study. Bangladesh J Dermatol Venereol Leprol. 2000;17:1\u20134.","journal-title":"Bangladesh J Dermatol Venereol Leprol."},{"key":"245_CR37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","volume":"115","author":"MF Muhlemann","year":"1986","unstructured":"Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227\u201332.","journal-title":"Br J Dermatol"},{"key":"245_CR38","first-page":"34","volume":"56","author":"N Vaswani","year":"1990","unstructured":"Vaswani N, Pandhi RK. Treatment of acne vulgaris with anti-androgens. Indian J Dermatol Venereol Leprol. 1990;56:34\u20136.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"245_CR39","first-page":"303","volume":"20","author":"XM Wang","year":"1991","unstructured":"Wang XM, Zhang XP, Li CH. Comparative observation on the therapeutic effect of acne vulgaris with spironolactone, ketoconazole and cimetidine. J Clin Dermatol. 1991;20:303\u20135.","journal-title":"J Clin Dermatol."},{"key":"245_CR40","first-page":"125","volume":"22","author":"G Azizlerli","year":"1988","unstructured":"Azizlerli G, \u00d6zarmagan G, Taklifi B, S\u00fcdogan S, Azizlerli H. Spironolactone therapy in acne patients [Aknede spironolatone ile tedavi]. Deri Hastal\u0131klar\u0131 ve Frengi Ar\u015fivi. 1988;22:125\u20139.","journal-title":"Deri Hastal\u0131klar\u0131 ve Frengi Ar\u015fivi"},{"key":"245_CR41","first-page":"265","volume":"6","author":"MS Beksac","year":"1990","unstructured":"Beksac MS, \u00d6nderglu LS, Atac B. Idiopathic hirsutism with spironolactone. Adv Contracept Deliv Syst. 1990;6:265\u20139.","journal-title":"Adv Contracept Deliv Syst."},{"key":"245_CR42","first-page":"231","volume":"37","author":"M Bravo Garcia","year":"1987","unstructured":"Bravo Garcia M, Barroeta S. Mejia de Alejos M, Franco de Arias M, Yustiz MA, Mascia S. Use of spironoactone in patients with acne [Uso de spironolactona en pacientes con acne]. Arch Argent Dermatol. 1987;37:231\u20138.","journal-title":"Arch Argent Dermatol"},{"key":"245_CR43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2133.1985.tb02305.x","volume":"112","author":"BM Burke","year":"1985","unstructured":"Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124\u20135.","journal-title":"Br J Dermatol"},{"key":"245_CR44","unstructured":"Cortez de Castro G, Pacheco A, Naranjo H, Palacios A. Spironolactone in thetreatment of acne [Espironolactona en el tratamiento del acne]. DermatologiaVenezolana. 1986;24:103\u20135."},{"key":"245_CR45","first-page":"1273","volume":"123","author":"V Hana","year":"1984","unstructured":"Hana V, Marek J, Gregorova I. Long-term treatment of hirsutism with spironolactone [Dlouhodoba lecba hirsutismu spirolaktonem]. Casopis Lekaru Ceskych. 1984;123:1273\u20135.","journal-title":"Casopis Lekaru Ceskych"},{"key":"245_CR46","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.1988.tb02571.x","volume":"118","author":"BR Hughes","year":"1988","unstructured":"Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol. 1988;118:687\u201391.","journal-title":"Br J Dermatol"},{"key":"245_CR47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2007.09.024","volume":"58","author":"A Krunic","year":"2008","unstructured":"Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008;58:60\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"245_CR48","first-page":"126","volume":"13","author":"E Lessner","year":"2014","unstructured":"Lessner E, Fisher S, Kobraei K, Osleber M, Lessner R, Elliot L, et al. Spironolactone and topical retinoids in adult female cyclical acne. J Drugs Dermatol. 2014;13:126\u20139.","journal-title":"J Drugs Dermatol"},{"key":"245_CR49","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/archderm.134.9.1162-a","volume":"134","author":"HG Lubbos","year":"1998","unstructured":"Lubbos HG, Hasinski S, Rose LI, Pollock J. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol. 1998;134:1162\u20133.","journal-title":"Arch Dermatol"},{"key":"245_CR50","unstructured":"Masahashi T, Wu MC, Ohsawa M. Spironolactone therapy for hyperandrogenic anovulatory women. Clinical and endocrinological study. Acta Obstet Gynaecol Jpn. 1986;38:95\u2013101."},{"key":"245_CR51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03350556","volume":"6","author":"M Messina","year":"1983","unstructured":"Messina M, Manieri C, Biffignandi P, Massucchetti C, Novi RF, Molinatti GM. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest. 1983;6:23\u20137.","journal-title":"J Endocrinol Invest"},{"key":"245_CR52","first-page":"1529","volume":"19","author":"M Pugeat","year":"1990","unstructured":"Pugeat M, Elmidani M, Dechaud H, Garoscio-Cholet M, Lejeune H, Tourniaire A. Treatment of hirsutism with spironolactone and progestagen combination [Traitement de l\u2019hirsutisme par l\u2019association de spironolactone et d\u2019un progestatif]. Presse Med. 1990;19:1529\u201332.","journal-title":"Presse Med"},{"key":"245_CR53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","volume":"151","author":"M Plovanich","year":"2015","unstructured":"Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151:941\u20134.","journal-title":"JAMA Dermatol."},{"key":"245_CR54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1468-3083.2010.03926.x","volume":"25","author":"M Saint-Jean","year":"2011","unstructured":"Saint-Jean M, Ballanger F, Nguyen JM, Khammari A, Dr\u00e9no B. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol. 2011;25:1480\u20131.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"245_CR55","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00266-006-0081-0","volume":"30","author":"K Sato","year":"2006","unstructured":"Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthet Plast Surg. 2006;30:689\u201394.","journal-title":"Aesthet Plast Surg."},{"key":"245_CR56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0190-9622(91)70034-Y","volume":"24","author":"JC Shaw","year":"1991","unstructured":"Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol. 1991;24:236\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"245_CR57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1067\/mjd.2000.105557","volume":"43","author":"JC Shaw","year":"2000","unstructured":"Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498\u2013502.","journal-title":"J Am Acad Dermatol"},{"key":"245_CR58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/120347540200600604","volume":"6","author":"JC Shaw","year":"2002","unstructured":"Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year follow up study. J Cutan Med Surg. 2002;6:541\u20135.","journal-title":"J Cutan Med Surg."},{"key":"245_CR59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yadr.2007.07.003","volume":"23","author":"CB Turowski","year":"2007","unstructured":"Turowski CB, James WD. The efficacy and safety of amoxicillin, trimethoprim-sulphamethoxazole and spironolactone for treatment resistant acne vulgaris. Adv Dermatol. 2007;23:155\u201363.","journal-title":"Adv Dermatol"},{"key":"245_CR60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","volume":"19","author":"A Yemisci","year":"2005","unstructured":"Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad DermatolVenereol. 2005;19:163\u20136.","journal-title":"J Eur Acad DermatolVenereol."},{"key":"245_CR61","unstructured":"Anonymous. Different concentrations of spironolactone in the treatment of acne. Chinese J Dermatol. 1989;22:258-9."},{"key":"245_CR62","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jc.2003-031122","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"245_CR63","first-page":"868","volume":"128","author":"E Devoto","year":"2000","unstructured":"Devoto E, Aravena L, Rios R. Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone. Rev Med Chil. 2000;128:868\u201375.","journal-title":"Rev Med Chil"},{"issue":"Suppl 1","key":"245_CR64","first-page":"251","volume":"84","author":"L Ibanez","year":"2015","unstructured":"Ibanez L, Diaz M, Sebastiani G, Lopez-Bermejo A, De F. Oral contraception vs low-dose pioglitazone-spironolactone-metformin for adolescent girls with hyperinsulinaemic androgen excess: on-treatment divergences. Horm Res Paediatr. 2015;84(Suppl 1):251\u20132.","journal-title":"Horm Res Paediatr."},{"key":"245_CR65","first-page":"1803","volume":"45","author":"RS Jurzyk","year":"1992","unstructured":"Jurzyk RS, Spielvogel RL, Rose LI. Antiandrogens in the treatment of acne and hirsutism. Am Fam Phys. 1992;45:1803\u20136.","journal-title":"Am Fam Phys."},{"key":"245_CR66","doi-asserted-by":"crossref","unstructured":"Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women. Retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine. 2009;88:32\u201345.","DOI":"10.1097\/md.0b013e3181946a2c"},{"key":"245_CR67","first-page":"49","volume":"32","author":"M Messina","year":"1990","unstructured":"Messina M, Manieri C, Musso MC, Pastorino R. Oral and topical spironolactone therapies in skin androgenization. Panminerva Med. 1990;32:49\u201355.","journal-title":"Panminerva Med"},{"key":"245_CR68","first-page":"579","volume":"115","author":"GM Molinatti","year":"1980","unstructured":"Molinatti GM, Messina M, Biffignandi P, Manieri C. Therapeutic possibilities in women with skin androgenic manifestations [Possibilita terapeutichein donne affette da manifestazionidi androgenizzazione a livello cutaneo]. G Ital Dermatol Venereol. 1980;115:579\u201384.","journal-title":"G Ital Dermatol Venereol"},{"key":"245_CR69","first-page":"599","volume":"122","author":"D Pizzino","year":"1987","unstructured":"Pizzino D, Bettoli V, Varotti C. Treatment of acne with antiandrogens: validity of treatment with spironolactone [Trattamento antiandrogeno dell\u2019acne: validata di unaterapia con spirolattone]. G Ital DermatolVenereol. 1987;122:599\u2013604.","journal-title":"G Ital DermatolVenereol"},{"key":"245_CR70","doi-asserted-by":"crossref","unstructured":"Shilin DE, Dedov II, Grigor\u2019eva EA. Thetherapeuticeffect of spironolactone in the hyperandrogenism syndrome [Lechebnyi effekt spironolaktona pri sindrome giperandrogenii]. Probl Endokrinol (Mosk).1993;39:55\u201360.","DOI":"10.14341\/probl11979"},{"key":"245_CR71","first-page":"41","volume":"32","author":"P Yl\u00f6stalo","year":"1987","unstructured":"Yl\u00f6stalo P, Heikkinen J, Kauppila A, Pakarinen A, J\u00e4rvinen PA. Low-dose spironolactone in the treatment of female hirsutism. Int J Fertil. 1987;32:41\u20135.","journal-title":"Int J Fertil."},{"key":"245_CR72","first-page":"224","volume":"63","author":"P Arenberger","year":"1988","unstructured":"Arenberger P, Vohradnikova O, Zaruba F. Treatment of acne vulgaris with spironolactone. Cesk Dermatol. 1988;63:224\u20137.","journal-title":"Cesk Dermatol."},{"key":"245_CR73","unstructured":"Cortez de Castro G, Pacheco A, Naranjo H, Palacios A. Acnevulgaris: treatment with spironolactone [Acne vulgar: tratamiento con espironolactona]. Salus Militia. 1987;12:34\u20137."},{"key":"245_CR74","first-page":"73","volume":"8","author":"JED Havrenne","year":"1985","unstructured":"Havrenne JED, Halbe HW. Treatment of idiopathic hirsutism with spironolactone [Tratamento do hirsutismo idiop\u00e1tico com espironolactona]. Ginecol Obstet Bras. 1985;8:73\u20134.","journal-title":"Ginecol Obstet Bras"},{"key":"245_CR75","first-page":"308","volume":"63","author":"O Vohradnikova","year":"1988","unstructured":"Vohradnikova O, Arenberger P, Kratochvilova M, Zaruba F. Treatment of acne vulgaris with spironolactone and Androcur. Cesk Dermatol. 1988;63:308\u201310.","journal-title":"Cesk Dermatol."},{"key":"245_CR76","first-page":"209","volume":"28","author":"A Yemisci","year":"1994","unstructured":"Yemisci A, Gorgulu A, Piskin S. Spironolactone therapy in acne vulgaris [Acne vulgaris tedavisinde spironolakton]. T\u00fcrkderm Deri Hastaliklari ve Frengi Arivi. 1994;28:209\u201312.","journal-title":"T\u00fcrkderm Deri Hastaliklari ve Frengi Arivi"},{"key":"245_CR77","first-page":"299","volume":"7","author":"C Cremoncini","year":"1976","unstructured":"Cremoncini C, Vignati E, Libroia A. Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol. Acta Eur Fertil. 1976;7:299\u2013314.","journal-title":"Acta Eur Fertil."},{"key":"245_CR78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.1977.01640010033003","volume":"113","author":"G Micha\u00eblsson","year":"1977","unstructured":"Micha\u00eblsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol. 1977;113:31\u20136.","journal-title":"Arch Dermatol"},{"key":"245_CR79","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/0378-6323.51244","volume":"75","author":"B Adityan","year":"2009","unstructured":"Adityan B, Thappa DM. Profile of acne vulgaris: a hospital-based study from South India. Indian J Dermatol Venereol Leprol. 2009;75:272\u20138.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"245_CR80","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1365-4362.1997.00099.x","volume":"36","author":"A Doshi","year":"1997","unstructured":"Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36:416\u20138.","journal-title":"Int J Dermatol"},{"key":"245_CR81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1984.tb04020.x","volume":"111","author":"BM Burke","year":"1984","unstructured":"Burke BM, Cunliffe WJ. The assessment of acne vulgaris: the Leeds technique. Br J Dermatol. 1984;111:83\u201392.","journal-title":"Br J Dermatol"},{"key":"245_CR82","first-page":"253","volume":"41","author":"P Caron","year":"1987","unstructured":"Caron P, Chateauneuf C, Bazex J, Louvet JP. Anti-seborrhea effect of cimetidine [Effet anti-s\u00e9borrh\u00e9e de cim\u00e9tidine]. Bio Med Pharmacother. 1987;41:253\u20134.","journal-title":"Bio Med Pharmacother"},{"key":"245_CR83","doi-asserted-by":"crossref","unstructured":"Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;(7):CD004425.","DOI":"10.1002\/14651858.CD004425.pub5"},{"issue":"8205","key":"245_CR84","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0140-6736(80)92640-9","volume":"2","author":"H Jones","year":"1980","unstructured":"Jones H, Simpson NB, Blanc D, Forster RA, Cunliffe WJ. Lack of effect of cimetidine in acne. Lancet. 1980;2(8205):1201\u20132.","journal-title":"Lancet"},{"key":"245_CR85","first-page":"423","volume":"22","author":"HS Wang","year":"1999","unstructured":"Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi. 1999;22:423\u201332.","journal-title":"Changgeng Yi Xue Za Zhi."},{"key":"245_CR86","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2006-2798","volume":"92","author":"J Calaf","year":"2007","unstructured":"Calaf J, Lopez E, Millet A, Alca\u00f1iz J, Fortuny A, Vidal O, et al. Long term efficacy and tolerability of flutamide compared with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007;92:3446\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"245_CR87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CCID.S20543","volume":"4","author":"H Adalatkhah","year":"2011","unstructured":"Adalatkhah H, Pourfarzi F, Sadeghi-Bazargani H. Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial. Clin Cosmet Investig Dermatol. 2011;4:117\u201321.","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"245_CR88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2265.2002.01594.x","volume":"57","author":"E Carmina","year":"2002","unstructured":"Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf). 2002;57:231\u20134.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"245_CR89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/09513590701214463","volume":"23","author":"C Kohler","year":"2007","unstructured":"Kohler C, Tschumi K, Bodmer C, et al. Effect of finasteride 5\u00a0mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23:142\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"245_CR90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jcem-71-2-335","volume":"71","author":"S Venturoli","year":"1990","unstructured":"Venturoli S, Fabbri R, Dal Prato L, Mantovani B, Capelli M, Magrini O, et al. Ketoconazole therapy for women with acne and\/or hirsutism. J Clin Endocrinol Metab. 1990;71:335\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"245_CR91","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1530\/eje.0.1300333","volume":"130","author":"AJ Vidal-Puig","year":"1994","unstructured":"Vidal-Puig AJ, Mu\u00f1oz-Torres M, J\u00f3dar-Gimeno E, Garc\u00eda-Calvente CJ, Lardelli P, Ruiz-Requena ME, et al. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol. 1994;130:333\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"245_CR92","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archderm.1986.01660180029008","volume":"122","author":"P Ghetti","year":"1986","unstructured":"Ghetti P, Patrone P, Tosti A. Ketoconazole in the treatment of acne in women. Arch Dermatol. 1986;122(6):629.","journal-title":"Arch Dermatol"},{"issue":"8131","key":"245_CR93","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(79)92011-7","volume":"1","author":"F Lyons","year":"1979","unstructured":"Lyons F, Cook J, Shuster S. Inhibition of sebum secretion by an H2 blocker. Lancet. 1979;1(8131):1376.","journal-title":"Lancet"},{"key":"245_CR94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/00016349009021041","volume":"69","author":"R Erkkola","year":"1990","unstructured":"Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990;69:61\u20135.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"245_CR95","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0010-7824(90)90002-D","volume":"42","author":"L Falsetti","year":"1990","unstructured":"Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1990;42:611\u20139.","journal-title":"Contraception."},{"key":"245_CR96","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/bmj.291.6504.1231","volume":"291","author":"R Greenwood","year":"1985","unstructured":"Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed). 1985;291:1231\u20135.","journal-title":"Br Med J (Clin Res Ed)."},{"key":"245_CR97","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2133.1986.tb04880.x","volume":"114","author":"JA Miller","year":"1986","unstructured":"Miller JA, Wojnarowska FT, Dowd PM. Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol. 1986;114:705\u201316.","journal-title":"Br J Dermatol"},{"key":"245_CR98","unstructured":"vanVloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4 Suppl):2\u201315."},{"key":"245_CR99","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13625180008500375","volume":"5","author":"J Huber","year":"2000","unstructured":"Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25\u201334.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"245_CR100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.contraception.2014.06.002","volume":"90","author":"U Jaisamrarn","year":"2014","unstructured":"Jaisamrarn U, Chaovisitsaree S, Angsuwathana S, Nerapusee O. A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial. Contraception. 2014;90:535\u201341.","journal-title":"Contraception."},{"key":"245_CR101","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/13625180008500411","volume":"5","author":"HI Katz","year":"2000","unstructured":"Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care. 2000;5:248\u201355.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"245_CR102","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/13625180500252638","volume":"11","author":"HT Kr\u00e4nzlin","year":"2006","unstructured":"Kr\u00e4nzlin HT, Nap MA. The effect of a phasic oral contraceptive containing desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care. 2006;11:6\u201313.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"245_CR103","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0010-7824(03)00167-7","volume":"68","author":"VN Prilepskaya","year":"2003","unstructured":"Prilepskaya VN, Serov VN, Zharov EV, Golousenko IJ, Mejevitinova EA, Gogaeva EV, et al. Effects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne. Contraception. 2003;68:239\u201345.","journal-title":"Contraception."},{"key":"245_CR104","first-page":"123","volume":"74","author":"IH Thorneycroft","year":"2004","unstructured":"Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123\u201330.","journal-title":"Cutis"},{"key":"245_CR105","first-page":"111","volume":"10","author":"P Pedrini De","year":"1988","unstructured":"De Pedrini P, Rapisarda R, Span\u00f2 G. The effect of ketoconazole on sebum secretion in patients suffering from acne and seborrhea. Int J Tissue React. 1988;10:111\u20133.","journal-title":"Int J Tissue React"},{"key":"245_CR106","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archderm.1987.01660270033010","volume":"123","author":"JF Norris","year":"1987","unstructured":"Norris JF, Cunliffe WJ. Effect of ketoconazole on sebum excretion rate. Arch Dermatol. 1987;123:301.","journal-title":"Arch Dermatol"},{"key":"245_CR107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000017850","volume":"196","author":"JB Schmidt","year":"1998","unstructured":"Schmidt JB. Other antiandrogens. Dermatology. 1998;196:153\u20137.","journal-title":"Dermatology"},{"issue":"3 Suppl","key":"245_CR108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0010-7824(98)00079-1","volume":"58","author":"BR Carr","year":"1998","unstructured":"Carr BR. Uniqueness of contraceptive progestins. Contraception. 1998;58(3 Suppl):23\u20137.","journal-title":"Contraception."},{"key":"245_CR109","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/1362518042000221508","volume":"9","author":"V Marmol del","year":"2004","unstructured":"del Marmol V, Teichmann A, Gertsen K. The role of combined oral contraceptives in the management of acne and seborrhea. Eur J Contracept Reprod Health Care. 2004;9:107\u201324.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"245_CR110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","volume":"61","author":"AE Schindler","year":"2008","unstructured":"Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171\u201380.","journal-title":"Maturitas."},{"key":"245_CR111","unstructured":"Friedman. Spironolactone for adult female acne. Cutis. 2015;96:216\u20137."},{"key":"245_CR112","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945\u201373.","journal-title":"J Am Acad Dermatol"},{"key":"245_CR113","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/jdv.12757","volume":"29","author":"B Dr\u00e9no","year":"2015","unstructured":"Dr\u00e9no B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S, Global Alliance to Improve Outcomes in Acne. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29:1096\u2013106.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"245_CR114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0190-9622(08)80534-8","volume":"26","author":"FW Danby","year":"1992","unstructured":"Danby FW. Spironolactone. J Am Acad Dermatol. 1992;26:137.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"245_CR115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bjd.13681","volume":"172","author":"V Bettoli","year":"2015","unstructured":"Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today. Br J Dermatol. 2015;172(Suppl 1):37\u201346.","journal-title":"Br J Dermatol"},{"key":"245_CR116","first-page":"236","volume":"96","author":"JQ Rosso Del","year":"2015","unstructured":"Del Rosso JQ, Harper JC, Graber EM, Thiboutot D, Silverberg NB, Eichenfield DZ, et al. Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 1: overview, clinical characteristics, and laboratory evaluation. Cutis. 2015;96:236\u201341.","journal-title":"Cutis"},{"key":"245_CR117","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jdv.13675","volume":"30","author":"HP Gollnick","year":"2016","unstructured":"Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30:1480\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"245_CR118","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jdv.13776","volume":"30","author":"A Nast","year":"2016","unstructured":"Nast A, Dreno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, et al. European evidence-based (S3) guideline for the treatment of acne\u2014update 2016\u2014short version. J Eur Acad Dermatol Venereol. 2016;30:1261\u20138.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"245_CR119","unstructured":"NICE Clinical Knowledge Summary. Acne 2014. cks.nice.org.uk\/acne-vulgaris. Accessed 3 Nov 2016 (not available outside the UK)."},{"key":"245_CR120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1346-8138.2011.01266.x","volume":"38","author":"F Abad-Casintahan","year":"2011","unstructured":"Abad-Casintahan F, Chow SK, Goh CL, Kubba R, Miyachi Y, Noppakun N, et al. Toward evidence-based practice in acne: consensus of an Asian Working Group. J Dermatol. 2011;38:1041\u20138.","journal-title":"J Dermatol"},{"key":"245_CR121","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/1346-8138.12993","volume":"42","author":"CL Goh","year":"2015","unstructured":"Goh CL, Abad-Casintahan F, Aw DC, Baba R, Chan LC, Hung NT, et al. South-East Asia study alliance guidelines on the management of acne vulgaris in South-East Asian patients. J Dermatol. 2015;42:945\u201353.","journal-title":"J Dermatol"},{"key":"245_CR122","unstructured":"CPG Secretariat. Management of acne. Malaysian clinical practice guideline 2012. http:\/\/www.moh.gov.my\/attachments\/7190.pdf . Accessed 3 Nov 2016."},{"issue":"Suppl 2","key":"245_CR123","first-page":"1","volume":"8","author":"A Nast","year":"2010","unstructured":"Nast A, Bayerl C, Borelli C, et al. S2\u00a0k-guideline for therapy of acne [in German]. J Dtsch Dermatol Ges. 2010;8(Suppl 2):1\u201359.","journal-title":"J Dtsch Dermatol Ges."},{"key":"245_CR124","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1503\/cmaj.140665","volume":"188","author":"Y Asai","year":"2016","unstructured":"Asai Y, Baibergenova A, Dutil M, et al. Management of acne: Canadian clinical practice guideline. Can Med Assoc J. 2016;188:118\u201326.","journal-title":"Can Med Assoc J"},{"key":"245_CR125","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","volume":"333","author":"P Brown","year":"2006","unstructured":"Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M. How to formulate research recommendations. BMJ. 2006;333:804\u20136.","journal-title":"BMJ"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0245-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T08:15:48Z","timestamp":1658564148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0245-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0245-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]}}}